AtriCure, Inc. (ATRC)
| Market Cap | 1.56B |
| Revenue (ttm) | 534.53M |
| Net Income (ttm) | -11.45M |
| Shares Out | 49.81M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | 248.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 508,369 |
| Open | 31.17 |
| Previous Close | 31.64 |
| Day's Range | 30.66 - 31.31 |
| 52-Week Range | 28.29 - 43.18 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 51.17 (+63.69%) |
| Earnings Date | Feb 17, 2026 |
About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation Sys... [Read more]
Financial Performance
In 2025, AtriCure's revenue was $534.53 million, an increase of 14.88% compared to the previous year's $465.31 million. Losses were -$11.45 million, -74.39% less than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ATRC stock is "Strong Buy." The 12-month stock price target is $51.17, which is an increase of 63.69% from the latest price.
News
AtriCure to Participate in the Citizens Life Sciences Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript
AtriCure, Inc. ( ATRC) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director C...
AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript
AtriCure, Inc. ( ATRC) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Pa...
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure to Announce Third Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...
AtriCure to Announce Second Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Ex...
AtriCure Reports First Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...